Proton pump inhibitor use was associated with an increased risk of gastric and oesophageal cancer.

PMID: 

Cancer Epidemiol. 2019 Aug 21 ;62:101585. Epub 2019 Aug 21. PMID: 31445426

Abstract Title: 

Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer.

Abstract: 

BACKGROUND: There is increasing interest in the potential association between proton pump inhibitors (PPIs) and the risk of gastric and oesophageal cancer, yet the effect of duration of treatment needs clarification.METHODS: This Swedish population-based cohort study assessed the influence of time since initiation of PPI treatment on the risk of gastric and oesophageal cancer, presented as standardised incidence ratios and 95% confidence intervals.RESULTS: The risk of gastric and oesophageal cancer during the first year was 7-10 times higher than the background population, and remained 24-202% increased without any decrease over time after the first year.CONCLUSION: PPI use was associated with an increased risk of gastric and oesophageal cancer and the risk remained increased over follow-up. These results support our original hypothesis that use of PPIs may be a risk factor for gastric and oesophageal cancer in the general population of maintenance users, independent of underlying indications.

read more